Market capitalization | $2.72b |
Enterprise Value | $2.23b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 5.55 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-147.15m |
Free Cash Flow (TTM) Free Cash Flow | $-110.10m |
Cash position | $492.54m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Edgewise Therapeutics Inc forecast:
7 Analysts have issued a Edgewise Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -2.16 -2.16 |
77%
77%
|
|
EBITDA | -145 -145 |
43%
43%
|
EBIT (Operating Income) EBIT | -147 -147 |
43%
43%
|
Net Profit | -124 -124 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
Head office | United States |
CEO | Kevin Koch |
Employees | 88 |
Founded | 2017 |
Website | www.edgewisetx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.